Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.

Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.

Vanderbilt’s Center for Technology Transfer and Commercialization generated nine new companies in 2020 and licensed a significant number of covid-related technologies.

Duke University will launch its Research Translation and Commercialization effort in July to expand its capacity to generate more spinouts and accelerate discoveries.

Weizmann Institute of Science participated in a series B round for its spinout that was originally known as OnSight Medical.

Kyoto University and University of Tokyo both participated in a series B round for the artwork-focused blockchain technology developer.

Appia Bio has emerged from stealth with $52m in series A financing to commercialise cancer treatments based on research at UCLA.

Atlantic Bridge has launched the University Bridge Fund II, with University College Cork joining existing partners Trinity College Dublin and University College Dublin.

MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.